How This UK MedTech Startup Just Accelerated Neurorehabilitation Tech

Jan de Vries · 2026-09-03

Here's a story that shows how innovation funding can really move the needle. Strolll, a MedTech company based in Stafford, UK, just secured a major financial boost to advance its augmented reality neurorehabilitation technology. And it's not just one source of funding—it's a combination that tells you something about their potential. They've landed a new investment round led by IW Capital, with notable participation from Cleveland Clinic and Future Planet Capital Regional. That's serious validation from both financial and clinical corners. But wait, there's more. Innovate UK has separately stepped in with two distinct awards that together total about $5.4 million in funding. That breaks down to a $4.5 million innovation loan and a $870,000 Growth Catalyst Investor Partnerships award. This comes on the heels of their $13.1 million Series A round back in March 2025, also led by IW Capital. ### What Strolll Actually Does Founded in 2018, Strolll develops what they call "software-as-a-medical-device" delivered through AR glasses. Think digital therapeutics for neurological disorders—patients can use their system for rehabilitation both in clinical settings and at home. The neurorehabilitation market is growing, frankly, because more people need these services. Strolll's approach aims to make therapy more engaging and accessible while giving clinicians better tools to support recovery. Jorgen Ellis, Strolll's CEO and co-founder, put it simply: "Our team is committed to revolutionizing rehabilitation for those living with neurological disorders. This funding will help us accelerate our mission." ### Where the Money is Going: Two Key Projects That $4.5 million innovation loan has a specific target: accelerating StrolllAssessment. This is a platform combining AI with what they're building as a fully equipped biomechanics lab. The goal? To mirror real-world rehab settings and dramatically speed up validation of digital assessments. Here's why that matters: validating clinical assessments traditionally takes years. Strolll claims their platform could shrink that to months while maintaining scalability and standards compliance. They're using AI to automate the clinical validation of digital neuromotor assessments. Part of the funding will establish that biomechanics lab right at their Stafford office. Then there's the second project funded by the $870,000 GCIP award plus over $1.2 million in investor funding. This is for StrolllAcute—a bedside-first AR rehabilitation system designed specifically for acute, bed-bound patients. The key insight here? It enables early therapeutic intervention without disrupting existing hospital workflows or adding to staff burden. ### Why This Funding Mix Matters Scott O’Brien, Chief Investment Officer at Innovate UK, highlighted what makes Strolll stand out: "Across two innovations, Strolll has secured Innovate UK backing because it has proven both its technical excellence and a credible route to commercial success." He pointed to their strategy of "de-risking later stage innovation through debt finance while providing grant alongside private capital" as exactly how public funding should work—providing the right support at the right time to accelerate innovation. What we're seeing here is more than just another funding announcement. It's a case study in how a MedTech startup can attract diverse funding sources by demonstrating both technological innovation and commercial viability. The combination of venture capital, strategic clinical partners, and public innovation funding creates a powerful foundation for growth. For anyone watching the European startup scene, especially in healthcare technology, Strolll's trajectory offers valuable insights. It shows how solving real clinical problems with thoughtful technology can attract the resources needed to scale impact.